Lenvatinib 4 mg is a targeted treatment for cancer that includes Lenvatinib as its active component, which is a powerful oral multi-kinase inhibitor. Lenvatinib, produced to deliver effective treatment for different types of advanced or metastatic cancers, is part of the medication class known as tyrosine kinase inhibitors (TKIs). This medication is mainly prescribed for patients with thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and other similar conditions.

Lenvatinib 4 mg functions by inhibiting several enzymes that contribute to the proliferation and dissemination of cancer cells, especially those that facilitate the development of blood vessels in tumors (angiogenesis). The drug slows or halts cancer progression by disrupting these processes.

Composition

Wirkstoff: Lenvatinib-Mesylat, das 4 mg Lenvatinib entspricht

Darreichungsform: Kapseln zum Einnehmen

Packaging: Usually comes in either a blister pack or a bottle, based on the manufacturer and distributor.

Indications and Uses

Lenvatinib is sanctioned for treating various cancers, such as:

Differenzierter Schilddrüsenkrebs (DTC)

For patients with locally recurrent or metastatic, progressive differentiated thyroid cancer (DTC) that does not respond to radioactive iodine treatment.

Hepatozelluläres Karzinom (HCC)

Initial therapy for unresectable liver cancer.

RCC (Renal Cell Carcinoma)

Utilized together with everolimus for patients who have undergone previous anti-angiogenic treatment.

Endometrium-Ca

Alongside pembrolizumab, applied to specific forms of advanced endometrial cancer that lack MSI-H or dMMR.

Mechanism of Action

Lenvatinib functions by blocking the activity of various receptor tyrosine kinases (RTKs) that play a role in tumor growth and the formation of new blood vessels. In particular, it aims at:

VEGFR1, VEGFR2, and VEGFR3 (Vascular Endothelial Growth Factor Receptors)

FGFR1–4 (Rezeptoren für fibroblastisches Wachstumsfaktor)

PDGFRα (Rezeptor alpha für plättchenabgeleiteten Wachstumsfaktor)

oncogenes RET and KIT

Lenvatinib hinders tumor growth and prevents the formation of new blood vessels (a process known as anti-angiogenesis) by blocking these signals.

Dosage and Administration

Standard Dosage: Lenvatinib is administered orally once a day, regardless of meals.

Personalized Therapy: The dosage depends on the cancer type, the patient’s body weight, and whether it is combined with other medications.

Important Tips:

Take the capsule with water without chewing.

To maintain consistent blood levels, take it daily at the same time.

The capsules should not be chewed or crushed.

When a dose is missed and there are less than 12 hours until the next scheduled dose, skip the missed one.

Important: It is essential to adhere strictly to the dosage prescribed by your oncologist or healthcare provider.

Precautions and Warnings

Before using Lenvatinib 4 mg, notify your physician if you:

Suffer from liver or kidney disease

Exhibit hypertension or cardiac issues

Are expecting, organizing pregnancy, or lactating

Do you take any other medications, including herbal supplements?

Important Warnings:

Pregnancy Risk: Lenvatinib may be harmful to an unborn child. During the period of treatment and for at least a month following the last dose, effective contraceptive methods should be employed.

Liver Toxicity: It is advisable to conduct regular liver function tests.

High Blood Pressure: Keep track of blood pressure regularly throughout treatment.

Bleeding and Wound Healing: There is a possibility of increased bleeding and interference with wound healing when using Lenvatinib.

Side Effects

Lenvatinib can cause side effects, as is the case with all medications. Typical examples are:

Müdigkeit

Appetite loss

Durchfall

Reduction of weight

Bluthochdruck

Pain in joints or muscles

Vomiting or nausea

Severe adverse effects (Contact a physician without delay):

Acute abdominal pain

Chest discomfort or difficulty breathing

Rapid alterations in vision

Symptoms of liver issues (skin turning yellow, dark-colored urine)

Amplified bleeding or contusions

Always inform your doctor about unusual symptoms without delay.

Storage Instructions

Keep at room temperature (20 °C to 25 °C).

Store the capsules in their original container, away from moisture and heat.

Make sure children and pets cannot reach it.

Do not take medication that has passed its expiration date. Dispose of it properly.

Conclusion

Lenvatinib is a potent and efficacious drug used to combat various aggressive cancers. Using its targeted action, tumor progression is slowed, and patient outcomes are improved in cases of advanced-stage cancer. Due to its powerful effects and possible side effects, it should be used only under the supervision of a medical professional. To attain optimal therapeutic outcomes with Lenvatinib, it is crucial to monitor regularly and comply with the prescribed guidelines.

Order Now At Mdx Pharma bd….

To order from MDX Pharma BD, visit their website at https://mdxpharmabd.com, where you can browse products and place orders online. For inquiries or orders via email, contact emedicarepharma@gmail.com. Alternatively, call (+88) 01929123476. Their address is 29, Abdullahpur, Uttara, Dhaka-1230, Bangladesh.

1. What is the purpose of Lenvatinib?
Lenvatinib is a targeted cancer therapy utilized for treating multiple cancer types, including thyroid, kidney (renal cell carcinoma), and liver (hepatocellular carcinoma) cancers, either as a standalone treatment or in conjunction with other drugs.

2. What is the mechanism of action of Lenvatinib?
Lenvatinib acts as a tyrosine kinase inhibitor (TKI). It inhibits specific proteins (VEGFR, FGFR, PDGFR, RET, and KIT) that facilitate the growth of cancer cells and the development of new blood vessels (angiogenesis), thus decelerating or halting tumor advancement.

3. What’s the proper way to take Lenvatinib 4 mg?
Administer it orally, precisely as your doctor has prescribed. It can be taken with or without meals, typically once daily. Take the capsule whole with some water and do not crush or chew it.

4. Is it possible to take Lenvatinib alongside other cancer therapies?
Depending on the specific type of cancer, Lenvatinib can be used alongside other treatments like pembrolizumab (a checkpoint inhibitor), particularly for advanced renal cell carcinoma or endometrial cancer.

5. Is Lenvatinib safe for women who are pregnant or breastfeeding?
Lenvatinib may be dangerous for an unborn child. Women need to avoid pregnancy during treatment and for at least 30 days following the final dose. During treatment and for a week after the last dose, breastfeeding is not advised.

6. What is the proper storage method for Lenvatinib 4 mg?
Keep it in a dry environment at room temperature (15°C to 30°C), away from direct light and moisture. Make sure children and pets cannot reach it.